Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer

On 14 September 2026, Elicio Therapeutics (ELTX) addressed investors at the H.C. Wainwright 28th Annual Global Investment Conference, delivering a mixed update on its progress. While early clinical signals remained promising, the company's lead randomized study, ELI-002, fell short of its primary goal. The company is now focusing on metastatic pancreatic cancer, a larger market with a faster path to later-stage testing.

Chief Scientific Officer Pete DeMuth detailed the company's lymph node-targeted immunotherapy strategy and the latest KRAS-focused ELI-002 program data. Shares of ELTX closed at $2, down 2.44% from the previous close of $2.05, trading near its 52-week low of $2.02 and down 87.5% from its 52-week high of $16. The stock was unchanged in after-hours trading at $2.

Elicio's Fair Value analysis suggests the stock may be slightly undervalued, but investors should note the company's weak overall financial health. The company plans to begin a Phase I metastatic pancreatic cancer trial in Q4 2024, with expected data in Q1 and Q2 2025.